Upadacitinib can be administered alone or in combination with methotrexate or DMARDs.416 Analysis of RA patient plasma proteins suggested that treatment with upadacitinib normalizes key pathways associated with RA pathobiology, including IL-1, IL-6, IFNγ, and TNF. This evidence concerns the gene TNF and rheumatoid arthritis.